Moxifloxacin
Moxifloxacin˼
¨ç ±Þ¼º ¼¼±Õ¼º ¾ó±¼ºÎÀ§°øµ¿¿°Áõ ¨è ¸¸¼º ±â°üÁö¿°ÀÇ °©ÀÛ½º·± ¾ÇÈ ¨é º´¿ø ¿Ü¿¡¼ ¾òÀº Æó¿° µî¿¡ °æ±¸ Ä¡·áÁ¦·Î ¾²ÀδÙ.
¨ç, ¨è, ¨éÀÇ ¿øÀαÕÀÌ moxifloxacin¿¡ »ç¸ê µÇ´Â ¹Ì»ý¹°ÀÏ °æ¿ì ±Þ¼º ¼¼±Õ¼º ¾ó±¼ºÎÀ§ °øµ¿¿°Áõ ȯÀÚ¿¡°Ô moxifloxacin°úcefuroxime axetilÀ» ºñ±³ÇÑ ÀÓ»ó ½ÇÇèÀº ÀÌµé µÎ °¡Áö Ç×»ý¹°ÁúÀÌ ÀÓ»ó Áõ»óÀ» 87% - 89% Ä¡·áµÈ´Ù´Â °ÍÀ» ¾Ë·Á ÁÖ°í ÀÖ´Ù.
Áߺ¹ °¨¿°(±³´ë °¨¿°) ¾øÀÌ Ä¡·áµÇ´Â °æ¿ì´Â moxifloxacinÀ¸·Î Ä¡·áÇÑ °æ¿ì¿¡´Â 95%ÀÌ°í cefuroxime axetil·Î Ä¡·áÇÑ °æ¿ì¿¡´Â 84%ÀÌ´Ù.
¸¸¼º ±â°üÁö¿°ÀÇ °©ÀÛ½º·± ¾ÇÈ È¯ÀÚ¿¡ ´ëÇÑ moxifloxacinÀÇ È¿°ú°¡ clarithro-mycin°ú ºñ±³µÇ¾ú´Ù.
moxifloxacin 5ÀÏ°£ Åõ¿©½Ã Ä¡·á À²Àº 89%·Î clarithromycin 7ÀÏ°£ Åõ¿© ½Ã Ä¡·áÀ² 88%¿Í ºñ½ÁÇÏ´Ù
ÀÌ ¿¬±¸¿¡¼ H. influenzae¿¡ ´ëÇÑ moxifloxacinÀÇ È¿°ú°¡ clarithromycinº¸´Ù ´õ ÁÁ´Ù°í Çß´Ù
Æó¿°±Õ¼º CAP ·Î ÃßÁ¤µÇ´Â ȯÀÚ¿¡°Ô 10ÀÏ°£ moxifloxacin°ú amoxicillinÀ» Åõ¿©, ºñ±³ÇÏ¿´´Ù.
MoxifloxacinÀÇ °æ¿ì´Â Ä¡·áÀ²Àº 91.5% Àç¹ß¹æÁöÀ²Àº 89.7%¿´°í, amoxicillinÀÇ °æ¿ì´Â Ä¡·áÀ²Àº 89.7%, Àç¹ß ¹æÁöÀ²Àº 82.4%¿´´Ù.
<¿ø¹®- Moxifloxacin>
Moxifloxacin is indicated for oral treatment of adults with acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis (AECB) and community acquired pneumonia(CAP) when these infections are caused by moxifloxacin-susceptible microorganisms.
A clinical study comparing moxifloxacin and cefuroxime axetil (Ceftin) in patients with acute bacterial sinusitis demonstrated that both antibacterials elicited nearly identical resolutions of clinical symptoms (87%-89%). Bacte-riological success without superinfec-tion was achieved in 95% of moxiflo-xacin-treated patients versus 84% in the case of cefuroxime axetil.
The efficacy of moxifloxacin in treating patients with AECB has been comp-ared with that of clarithromycin (Bi-axin). The cure rates for a 5-day co-urse of moxifloxacin versus a 7-day course of clarithromycin were nearly identical, 89% and 88%, respectively.
In this study, moxifloxacin was claim-ed to be more effective microbiologi-cally than clarithromycin, particularly against H. influenzae. Ten-day cour-ses of moxifloxacin and amoxicillin(Amoxil) were compared in patients with a presumptive diagnosis of pneumococcal CAP. Clinical success was achieved in 91.5% of moxifloxacin and 89.7% of amoxicillin < ÀúÀÛ±ÇÀÚ © ¾à±¹½Å¹® ¹«´ÜÀüÀç ¹× Àç¹èÆ÷±ÝÁö > |
|
|
|
|
ÀÌ ±â»ç¿¡ ´ëÇÑ ´ñ±Û À̾߱â (0) |
|
|
|